Shots:

• The P-III PROfound study involves assessing of Lynparza vs enzalutamide or abiraterone in patients with mCRPC- progressed on prior treatment with NHA treatments (abiraterone or enzalutamide) along with tumor mutation in BRCA1/2- ATM or one of 12 other genes involved in the HRR pathway
• The P-III PROfound study demonstrated improvement in OS and is already met its 1EPs i.e. improvement in rPFS in men with mutations in BRCA1/2 or ATM genes in Aug’2019 and a 2EPs of rPFS in the overall HRRm population  
• Lynparza is a first-in-class PARP inhibitor acts by targeting DDR in cells/tumors harboring a deficiency in HRR (BRCA1& 2 mutation) and has received the US FDA’s PR designation for patients with HRRm mCRPC in Jan’20. Additionally- the companies are working on ongoing P-III PROpel trial with its expected results in 2021

Click here to­ read full press release/ article 

Ref: AstraZeneca | Image: AstraZeneca